🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Party Like It's 2015: Celebrate the 10th Anniversary of Timmerman Report in March. Free, fun events in Boston and Seattle. Register today! timmermanreport.com/2025/01/party-…

Timmerman Report Turns 10. timmermanreport.com/2025/02/timmer…

DeepSeek Shocked Silicon Valley, but It Didn't Shake the Earth in Biotech. By Simon Barnett DIMENSION timmermanreport.com/2025/02/deepse…

Zero-Toll Medicine. Thought-provoking guest editorial by D.A. Wallach on how to fix what's broken in US health insurance. timmermanreport.com/2025/02/zero-t…

Defend Young Scientists. timmermanreport.com/2025/02/stand-…

How Maze Therapeutics Navigated Genetics-based Drug Discovery. By co-founder and former CSO Eric Green. (Sub. Req.) timmermanreport.com/2025/02/how-ma…

Bluebird Fire Sale, Regeneron Gene Therapy for Deafness, & Eikon Raises a Bundle. The weekly Frontpoints column. (Sub. Req.) timmermanreport.com/2025/02/bluebi…

Biotech Legend Retires, Jazz Buys Glioma Drug, & FDA Shakeup. Frontpoints column. (Sub. Req.). timmermanreport.com/2025/03/biotec…

Standing up for Science. A report from the protest in Seattle. timmermanreport.com/2025/03/scient…

Protagonist Delivers, BMS Bargain Hunts, & Zealand Goes Major Leagues. The weekly Frontpoints column. (Sub. Req.) timmermanreport.com/2025/03/protag…

Arbor Survives Winter, Gets $73.9M to Take Gene Editing Therapy to the Clinic. timmermanreport.com/2025/03/arbor-…

Curevo and Arbor Defy Gravity, Cargo Hits the Wall, & AZ Bets on In Vivo. Frontpoints column. (Sub. Req.) timmermanreport.com/2025/03/curevo…

How a Dark Horse Candidate Is Upending the Sequencing Market. By Joe Horsman, biotech investor Madrona timmermanreport.com/2025/03/how-a-…

NIH Cuts Threaten to Cede US Life Science Dominance to China. Editorial by state biotech leaders from Ohio, North Carolina, Washington and Michigan. timmermanreport.com/2025/03/nih-cu…

A Moment of Peril and Promise. (Sub. Req). timmermanreport.com/2025/03/soleno…

Goal: the 2025 Timmerman Traverse for Damon Runyon Cancer Research Foundation has hit the fundraising goal of $700,000 for high-risk / high-reward cancer research. Team gearing up for trek to Everest Base Camp. timmermanreport.com/2025/04/timmer…

mRNA vaccines and therapies are facing a backlash. Vaccine researcher Lawrence Corey explains why this technology platform needs a superhero. timmermanreport.com/2025/04/we-nee…

Reclaiming Biotech's Edge: In Defense of Taking Disciplined Risk. By Anika Gupta timmermanreport.com/2025/05/reclai…

GlycoEra Grabs $130M Series B to Make Extracellular Degraders for Autoimmunity. (Sub. Req). timmermanreport.com/2025/05/glycoe…

Request an Invitation to the Timmerman Traverse. timmermanreport.com/2025/06/reques…